Bizi ohitura osasuntsuak sustatzeko jarduera fisiko programak Portugaleten

[EUS] Bizi ohitura osasuntsuak osatzen duten pautak ezartzea eta Portugaleteko kasura bideratzea da lan honen helburu nagusia. Horretarako, gaur egungo egoera zein den planteatu eta hobekuntzak proposatuko ditugu biztanleria aktiboagoa eta bizi ohitura osasuntsuagoak izateko asmoarekin. Portugaleteko jarduera fisiko eta kiroleko egoera aztertuko da, baita eskaintza eta udalaren jarduera maila ere, Portugaleteko kirol errealitatea zein den ezagutzeko helburuarekin. Lanaren datuak eta ondorioak testu inguratzeko, jarduera fisiko eta ohitura osasuntsuak osatzen duten kontzeptuei birpasa bat aurkeztuko dugu. Amaitzeko, Portugalete kasurako aplikagarriak diren proiektu batzuk proposatuko ditugu.[ES] El objetivo principal del trabajo que viene a continuación es establecer pautas que componen hábitos de vida saludables para ponerlo en práctica al caso de Portugalete. Para ello, se analizará cual es la situación actual para que la ciudadanía sea más activa y tenga hábitos de vida más saludables.Se analizará la situación de la actividad física y el deporte en Portugalete, la oferta y el nivel de actividad desde el Ayuntamiento, con el objetivo de conocer la realidad de Portugalete. Para poner en contexto los datos y conclusiones del trabajo, haremos un repaso a los conceptos de actividad física y deporte. Para finalizar, propondremos varios proyectos aplicables a la realidad de Portugalete

Bizi ohitura osasuntsuak sustatzeko jarduera fisiko programak Portugaleten

[EUS] Bizi ohitura osasuntsuak osatzen duten pautak ezartzea eta Portugaleteko kasura bideratzea da lan honen helburu nagusia. Horretarako, gaur egungo egoera zein den planteatu eta hobekuntzak proposatuko ditugu biztanleria aktiboagoa eta bizi ohitura osasuntsuagoak izateko asmoarekin. Portugaleteko jarduera fisiko eta kiroleko egoera aztertuko da, baita eskaintza eta udalaren jarduera maila ere, Portugaleteko kirol errealitatea zein den ezagutzeko helburuarekin. Lanaren datuak eta ondorioak testu inguratzeko, jarduera fisiko eta ohitura osasuntsuak osatzen duten kontzeptuei birpasa bat aurkeztuko dugu. Amaitzeko, Portugalete kasurako aplikagarriak diren proiektu batzuk proposatuko ditugu.[ES] El objetivo principal del trabajo que viene a continuación es establecer pautas que componen hábitos de vida saludables para ponerlo en práctica al caso de Portugalete. Para ello, se analizará cual es la situación actual para que la ciudadanía sea más activa y tenga hábitos de vida más saludables.Se analizará la situación de la actividad física y el deporte en Portugalete, la oferta y el nivel de actividad desde el Ayuntamiento, con el objetivo de conocer la realidad de Portugalete. Para poner en contexto los datos y conclusiones del trabajo, haremos un repaso a los conceptos de actividad física y deporte. Para finalizar, propondremos varios proyectos aplicables a la realidad de Portugalete

Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials

Abstract Background Convalescent plasma has been widely used to treat COVID-19 and is under investigation in numerous randomized clinical trials, but results are publicly available only for a small number of trials. The objective of this study was to assess the benefits of convalescent plasma treatment compared to placebo or no treatment and all-cause mortality in patients with COVID-19, using data from all available randomized clinical trials, including unpublished and ongoing trials (Open Science Framework, https://doi.org/10.17605/OSF.IO/GEHFX ). Methods In this collaborative systematic review and meta-analysis, clinical trial registries (ClinicalTrials.gov, WHO International Clinical Trials Registry Platform), the Cochrane COVID-19 register, the LOVE database, and PubMed were searched until April 8, 2021. Investigators of trials registered by March 1, 2021, without published results were contacted via email. Eligible were ongoing, discontinued and completed randomized clinical trials that compared convalescent plasma with placebo or no treatment in COVID-19 patients, regardless of setting or treatment schedule. Aggregated mortality data were extracted from publications or provided by investigators of unpublished trials and combined using the Hartung–Knapp–Sidik–Jonkman random effects model. We investigated the contribution of unpublished trials to the overall evidence. Results A total of 16,477 patients were included in 33 trials (20 unpublished with 3190 patients, 13 published with 13,287 patients). 32 trials enrolled only hospitalized patients (including 3 with only intensive care unit patients). Risk of bias was low for 29/33 trials. Of 8495 patients who received convalescent plasma, 1997 died (23%), and of 7982 control patients, 1952 died (24%). The combined risk ratio for all-cause mortality was 0.97 (95% confidence interval: 0.92; 1.02) with between-study heterogeneity not beyond chance (I2 = 0%). The RECOVERY trial had 69.8% and the unpublished evidence 25.3% of the weight in the meta-analysis. Conclusions Convalescent plasma treatment of patients with COVID-19 did not reduce all-cause mortality. These results provide strong evidence that convalescent plasma treatment for patients with COVID-19 should not be used outside of randomized trials. Evidence synthesis from collaborations among trial investigators can inform both evidence generation and evidence application in patient care

Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials

Abstract Background Convalescent plasma has been widely used to treat COVID-19 and is under investigation in numerous randomized clinical trials, but results are publicly available only for a small number of trials. The objective of this study was to assess the benefits of convalescent plasma treatment compared to placebo or no treatment and all-cause mortality in patients with COVID-19, using data from all available randomized clinical trials, including unpublished and ongoing trials (Open Science Framework, https://doi.org/10.17605/OSF.IO/GEHFX ). Methods In this collaborative systematic review and meta-analysis, clinical trial registries (ClinicalTrials.gov, WHO International Clinical Trials Registry Platform), the Cochrane COVID-19 register, the LOVE database, and PubMed were searched until April 8, 2021. Investigators of trials registered by March 1, 2021, without published results were contacted via email. Eligible were ongoing, discontinued and completed randomized clinical trials that compared convalescent plasma with placebo or no treatment in COVID-19 patients, regardless of setting or treatment schedule. Aggregated mortality data were extracted from publications or provided by investigators of unpublished trials and combined using the Hartung–Knapp–Sidik–Jonkman random effects model. We investigated the contribution of unpublished trials to the overall evidence. Results A total of 16,477 patients were included in 33 trials (20 unpublished with 3190 patients, 13 published with 13,287 patients). 32 trials enrolled only hospitalized patients (including 3 with only intensive care unit patients). Risk of bias was low for 29/33 trials. Of 8495 patients who received convalescent plasma, 1997 died (23%), and of 7982 control patients, 1952 died (24%). The combined risk ratio for all-cause mortality was 0.97 (95% confidence interval: 0.92; 1.02) with between-study heterogeneity not beyond chance (I2 = 0%). The RECOVERY trial had 69.8% and the unpublished evidence 25.3% of the weight in the meta-analysis. Conclusions Convalescent plasma treatment of patients with COVID-19 did not reduce all-cause mortality. These results provide strong evidence that convalescent plasma treatment for patients with COVID-19 should not be used outside of randomized trials. Evidence synthesis from collaborations among trial investigators can inform both evidence generation and evidence application in patient care